The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 26, 2022
Filed:
Sep. 02, 2016
Applicant:
Syndax Pharmaceuticals, Inc., Waltham, MA (US);
Inventor:
Peter Ordentlich, Lexington, MA (US);
Assignee:
SYNDAX PHARMACEUTICALS, INC., Waltham, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); G01N 33/574 (2006.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); A61K 31/4406 (2006.01); A61K 31/5685 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); A61K 31/4406 (2013.01); A61K 31/5685 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2827 (2013.01); G01N 33/5091 (2013.01); G01N 33/56972 (2013.01); C07K 2317/24 (2013.01); G01N 2800/52 (2013.01);
Abstract
Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.